Home Journals Articles Updates About
CN
image
收藏切换
siRNA therapy for metabolic dysfunction-associated steatotic liver disease
收藏切换
Yu-xiao LIU, Xing-feng LIU, Wen-jia FAN, Ping-ping LI*
Acta Pharmaceutica Sinica | 2026, 61(9) : 3302 - 3315
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(9): 3302-3315
• Reviews •
siRNA therapy for metabolic dysfunction-associated steatotic liver disease
Full
Yu-xiao LIU, Xing-feng LIU, Wen-jia FAN, Ping-ping LI*
Affiliations
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Published: 2026-09-12 doi: 10.16438/j.0513-4870.2026-0264
Outline
收藏切换

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most prevalent chronic liver disease worldwide. Its pathogenesis involves the interplay of lipid dysregulation, insulin resistance, oxidative stress, inflammation, gut microbiota dysbiosis, and genetic susceptibility variants. Current therapeutic interventions primarily rely on systemic administration, with their hepatic specificity or selectivity remaining to be improved. Small interfering RNA (siRNA) therapy offers a novel strategy by precisely silencing hepatic pathogenic genes to block aberrant protein synthesis. This review outlines the mechanisms of action and the delivery systems of siRNA therapeutics. Focusing on the core pathological drivers of MASLD, it details the clinical progress and mechanistic insights of siRNA therapeutics within three main areas: Genetic risk variants, lipid metabolism regulation, and fibrosis-inflammation pathways. This article provides an updated reference for siRNA drug development in MASLD.

metabolic dysfunction-associated steatotic liver disease  /  liver targeting  /  small interfering RNA  /  gene silencing  /  delivery system
刘玉骁, 柳星峰, 范雯嘉, 李平平. 代谢功能障碍相关脂肪性肝病的小干扰RNA治疗. 药学学报, 2026 , 61 (9) : 3302 -3315 . DOI: 10.16438/j.0513-4870.2026-0264
Yu-xiao LIU, Xing-feng LIU, Wen-jia FAN, Ping-ping LI. siRNA therapy for metabolic dysfunction-associated steatotic liver disease[J]. Acta Pharmaceutica Sinica, 2026 , 61 (9) : 3302 -3315 . DOI: 10.16438/j.0513-4870.2026-0264
Appendix
Less
Year 2026 volume 61 Issue 9
214
100
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2026-0264
  • Receive Date：2026-03-11
  • Online Date：2026-10-22
  • Published：2026-09-12
Article Data
Affiliations
History
  • Received：2026-03-11
  • Revised：2026-04-14
Affiliations
    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2026-0264
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House